Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
Alderley Park, Cheshire, U.K. – 12 May 2026, Infex Therapeutics, a leading…
World AMR Awareness Week 2025
This World AMR Awareness Week, we're proud to be celebrating our collaboration…
UK Government investment is vital to combat AMR
Professor Janet Hemingway, iiCON Founding Director Dr Pete Jackson,…
Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired…
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
First NCFB patient dosed in Phase IIa study of RESP-X
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex invites you to Alderley Park's 10th Anniversary SciTech Extravaganza
Saturday 14 September, 10:00am - 3:00pm Come and join us in Glasshouse at…
Infex to present RESP-X Phase I data at ERS Congress
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex strengthens its senior leadership team
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
